Shanghai Bio-Heart Biological Technology Co., Ltd. engages in the research and development of interventional cardiovascular device therapies. It focuses on bioresorbable scaffold therapy addressing the unmet medical needs of Chinese patients for the treatment of coronary or peripheral artery diseases and renal denervation therapy addressing the unmet medical needs of patients for the treatment of uncontrolled hypertension and resistant hypertension. The company was founded by Li Wang and Guo Hui Wang on July 18, 2014 and is headquartered in Shanghai, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company